Equities analysts forecast that TG Therapeutics, Inc. (NASDAQ:TGTX) will report earnings per share (EPS) of ($0.46) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for TG Therapeutics’ earnings. TG Therapeutics posted earnings of ($0.50) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 8%. The firm is scheduled to announce its next earnings report on Monday, November 6th.
According to Zacks, analysts expect that TG Therapeutics will report full-year earnings of ($1.79) per share for the current fiscal year, with EPS estimates ranging from ($1.89) to ($1.54). For the next year, analysts anticipate that the firm will post earnings of ($1.54) per share, with EPS estimates ranging from ($1.92) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.01. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%.
Several brokerages have recently issued reports on TGTX. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a report on Monday, May 1st. BidaskClub lowered TG Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, July 6th. Zacks Investment Research downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of TG Therapeutics in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $25.40.
Shares of TG Therapeutics (NASDAQ:TGTX) traded down 4.18% during trading on Friday, hitting $11.45. 865,395 shares of the stock traded hands. The company’s market cap is $713.45 million. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.35. The stock has a 50-day moving average of $11.05 and a 200 day moving average of $10.43.
In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction on Monday, June 19th. The stock was sold at an average price of $11.09, for a total value of $665,133.84. Following the sale, the chief financial officer now owns 477,464 shares in the company, valued at $5,295,075.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 16.70% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its stake in TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 384 shares in the last quarter. Creative Planning boosted its position in TG Therapeutics by 3.2% in the first quarter. Creative Planning now owns 32,001 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 1,000 shares during the last quarter. Bank of America Corp DE boosted its position in TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,395 shares during the last quarter. American International Group Inc. boosted its position in TG Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 22,681 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 1,500 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in TG Therapeutics by 1.9% in the second quarter. California State Teachers Retirement System now owns 85,935 shares of the biopharmaceutical company’s stock valued at $864,000 after buying an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 46.53% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Get a free copy of the Zacks research report on TG Therapeutics (TGTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
